GILD Stock Price Today (September 2026) — Gilead Sciences, Inc. Analysis & Key Metrics 2026-09-04
Gilead Sciences, Inc. (GILD) is trading at $151.00, down 0.15% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $157.41 (4.2% upside).
- Volatility remains elevated (23.27% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside significant competitive pressures.
GILD Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Gilead Sciences, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $201.92B
P/E Ratio
Forward P/E: 14.80
Revenue Growth
Year over Year
Analyst Target
+4.2% upside potential
Key Investor Questions About GILD
What investors need to know before buying
Based on current market data, GILD presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 70.20)
- Fundamentals say: Caution warranted (high leverage concerns)
GILD's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GILD investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $26.25B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, GILD stock traded between $108.46 and $157.29—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.27% annualized volatility and β=0.43, the stock exhibits low sensitivity to market moves—making GILD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Gilead Sciences Stock Outperforming the S&P 500?
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Explore More Analysis for GILD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is currently trading at $151.00. The RSI (14-day) is at 70.2, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $157.41 implies 4.2% upside from current levels. Volatility is moderate at 23.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Gilead Sciences, Inc. (GILD): The trailing P/E ratio is -56.98, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 14.80. Price-to-Book is 15.84. Price-to-Sales is 6.15. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering GILD, the consensus price target is $157.41. This represents a 4.2% upside from the current price of $151.00. The range spans from a low target of $123.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a current yield of approximately 2.17%. The annualized dividend rate is $3.22 per share. The payout ratio is 43.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-09-15T00:00:00.000Z.
Key risks for Gilead Sciences, Inc. (GILD) investors include: 1. Elevated debt levels (D/E ratio of 223.47) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Gilead Sciences, Inc.'s (GILD) current debt and financial health profile: Total debt stands at $26.25B. The debt-to-equity ratio is 223.47, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.26, indicating adequate short-term liquidity. The quick ratio is 0.90. The company holds $4.88B in cash and equivalents. Free cash flow is positive at $9.77B, providing a cushion for debt servicing and shareholder returns.